Research and Markets: Biomarker Partnering Terms & Agreements

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/87v33r/biomarker) has announced the addition of the "Biomarker Partnering Terms & Agreements" report to their offering.

The Biomarker Partnering Terms & Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the world's leading healthcare companies.

- Trends in biomarker partnering deals

- Biomarker partnering agreement structure

- Biomarker partnering contract documents

- Top biomarker deals by value

- Most active biomarker dealmakers

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1000 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Companies Mentioned

- Abbott

- Amgen

- Astellas

- AstraZeneca

- Bayer

-Biogen Idec

- Boehringer Ingelheim

- Bristol-Myers Squibb

- Celgene

- Eli Lilly

- GlaxoSmithKline

- Johnson & Johnson

- Merck & Co

- Merck KGaA

- Novartis

- Pfizer

- Roche

- Sanofi

- Servier

- Takeda

- UCB

For more information visit http://www.researchandmarkets.com/research/87v33r/biomarker